Ausun Pharm(SH:603229)2023-08-29 16:00Financial Performance - The company's operating revenue for the first half of 2023 reached ¥468,715,612.42, representing a 22.91% increase compared to ¥381,360,543.87 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥160,196,748.33, up 30.22% from ¥123,023,476.54 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥153,232,464.11, reflecting a 30.68% increase from ¥117,259,671.95 year-on-year[19]. - The net cash flow from operating activities was ¥40,463,326.85, a significant increase of 60.03% compared to ¥25,285,282.43 in the same period last year[19]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,095,249,484.09, a 43.40% increase from ¥1,461,140,520.64 at the end of the previous year[19]. - Total assets increased by 30.14% to ¥3,013,263,821.39 from ¥2,315,330,188.78 at the end of the previous year[19]. - Basic earnings per share for the first half of 2023 increased to CNY 0.27, up 22.73% from CNY 0.22 in the same period last year[20]. - Diluted earnings per share also rose to CNY 0.27, reflecting a 22.73% increase compared to the previous year[20]. Research and Development - The company has established a research and development team of over 200 members, focusing on various aspects of drug development and production optimization[44]. - The company invested 47.90 million yuan in R&D, representing 10.22% of operating revenue, to enhance product development capabilities[52]. - Research and development expenses increased by 66.52% to CNY 47,902,225.02, up from CNY 28,767,285.27, primarily due to increased employee compensation and design testing costs[56][57]. - The company is actively developing a new drug, Brozospin Sodium, for ischemic stroke, with Phase I studies completed and Phase II trials concluded[46]. - The company is developing a new Class 1 drug for the treatment of ischemic stroke, with Phase II clinical trials completed and awaiting Phase III[26]. Market and Industry Trends - The global pharmaceutical market size grew from $1,208.4 billion in 2017 to $1,401.2 billion in 2021, with a projected CAGR of 5.2% from 2021 to 2025, reaching $1,718.8 billion by 2025[31]. - The global CRO market size increased from $40.1 billion in 2014 to $71.9 billion in 2021, with a CAGR of 8.7%, and is expected to reach $95.2 billion in 2023[33]. - The global CDMO market size rose from $39.4 billion in 2017 to $63.2 billion in 2021, with a CAGR of 12.5%, projected to reach $124.3 billion by 2025[34]. - China's pharmaceutical market expanded from ¥1,430.4 billion in 2017 to ¥1,591.2 billion in 2021, with a CAGR of 2.7%, expected to reach ¥2,064.5 billion by 2025[36]. - The innovative drug market in China accounted for 59.5% of the overall pharmaceutical market in 2021, with a projected market size of ¥1,401 billion by 2025[37]. Environmental Compliance and Sustainability - The company has established a wastewater treatment system with a capacity of 600 tons per day and an organic waste gas RTO incineration device with a capacity of 38,000 cubic meters per hour[80]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating a focus on environmental compliance and sustainability[78]. - Environmental self-monitoring plans have been implemented, with third-party monitoring showing that all pollutant indicators meet discharge standards[84]. - The company has committed to avoiding competition with its own business in any other organizations controlled by its shareholders[87]. Financial Position and Capital Management - The total amount of guarantees provided by the company to subsidiaries during the reporting period was RMB 35,000.00 million[95]. - The total amount of guarantees, including those to subsidiaries, accounted for 16.70% of the company's net assets[95]. - The company approved a guarantee limit of up to RMB 60,000.00 million for its wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical Co., Ltd.[95]. - The total number of shares increased to 423,620,992 after a non-public offering of 21,754,288 shares, representing 5.14% of the total share capital[100]. - The company distributed a cash dividend of CNY 0.112 per share, totaling CNY 47,445,551.10, and increased capital by 0.4 shares per existing share, resulting in a total of 593,069,389 shares post-distribution[147]. Operational Highlights - The CRO/CDMO/CMO business segment has gained recognition in the international market, becoming a strategic supplier for several large pharmaceutical companies[26]. - The company achieved operating revenue of 468.72 million yuan, a year-on-year increase of 22.91%[49]. - The CRO/CDMO/CMO business generated sales revenue of 229.86 million yuan, accounting for 49.04% of total operating revenue[49]. - The company has completed multiple series of raw materials and intermediates, ready for scale sales following patent expirations of target drugs[44]. - The company is focusing on expanding its customer base, particularly in Europe, the US, and Japan, to enhance sales proportions in these markets[52]. Risk Management - The company has not experienced any major safety production accidents as of the report date, but risks remain due to potential equipment and operational issues[73]. - The company’s export business is significantly impacted by exchange rate fluctuations, which can affect operating performance[73]. - The company has faced rising raw material prices, which have increased production costs and pressured profit margins[73]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 32,249[105]. - The top shareholder, Zheng Zhiguo, holds 214,506,991 shares, representing 50.64% of the total shares[107]. - The total shares held by the top ten shareholders amount to 254,000,000 shares, which is approximately 61.12% of the total shares[107]. - The company has no preferred shareholders with restored voting rights as of the end of the reporting period[105]. Compliance and Governance - The company has not reported any violations or penalties involving its directors, supervisors, or senior management during the reporting period[92]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[90]. - The company confirmed no major guarantees during the reporting period[91].